info@clinicaloncologyjournal.com

Antonia Digklia

Antonia Digklia

Antonia Digklia

MD Lausanne University Hospital, Department of Oncology Switzerland

BIOGRAPHY 17 PUBLICATIONS 41

We cordially invite you to join our board.

Your valuable suggestions improve our journal quality. We welcome you to be part of our board members.

Join Board

Work and Research Experience

  • Aug 2019-onwards: Head of GI/Pancreatic-liver-biliary unit - Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Department, Lausanne, Switzerland.
  • Jan. 2014-Aug 2019: Junior Consultant at the Department of Oncology GI, Interventional radiology and Sarcoma Unit - Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Department, Lausanne, Switzerland.
  • Jan. 2015-onwards: Active member Working Group Sarcoma of SAKK (Swiss Group for Clinical Cancer Research).
  • Dec. 2012-May 2013: Role of MLF1IP and TTK in breast cancer cell line MB-231 (Supervisors: Dr. A. Wolfer) - University of Lausanne, Institute of Pathology, Lausanne, Switzerland.
  • Apr. 2010-Jan. 2014: Resident at the Department of Oncology  (Supervisors: Prof. G.Coukos) - Centre Hospitalier Universitaire Vaudois (CHUV), Oncology Department, Lausanne, Switzerland.
  • Apr.2008-Apr. 2010: Resident at the Department of Internal Medicine (Supervisors: Dr. H. Duplain MD) - Hopîtal du Jura Delémont, Switzerland.
  • Nov. 2007-Apr. 2008: Resident at the Department of Internal Medicine and Gastroenterology (Supervisors: Dr. D. Bernard MD, Dr. J. Bottlaender MD) - Hopîtal Universitaire de Strasbourg, Strasbourg, France.
  • Nov. 2006-May. 2007: Resident at the Department of Internal Medicine - Hopîtal de Selestat, Selestat, France.
  • Aug. 2006: Volunteer resident at the Department of Pediatrics (Supervisor: Dr. P. Mpotis) - Tzaneio General Hospital, Athens, Greece.

Studies

  • 2016: Doctoral thesis Unil (University of Lausanne).
  • March 2016 and 2012: Courses on Research Ethics and GCP (Investigator level)-Swiss Ethics Comittees on research involving humans.
  • Oct. 2013: Oral examination Swiss Society of Medical Oncology SSMO (succcessfully).
  • Sep. 2012: ESMO examination in Medical Oncology (succcessfully).
  • Sep. 2010-June 2013: Master student in Molecular Biology - University of Strasbourg, Institute de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France.
  • Αpril 2010: MD  Title - FMH Examination in Internal Medicine (Swiss Society of Internal Medicine).
  • Sep. 2000-Aug. 2006: Medical School (Diploma grade : Very good) - National and Kapodistrian University of Athens, Athens, Greece.
  • Sep. 1997-Jun. 2000: High school of Astros (General note: 19.7/20), Astros, Greece.
  • Phillips E, Huang P, Robin J, Digklia A. Eribulin in Soft tissue sarcoma, Frontiers Oncology 2022 (accepted)
  • Digklia A, Coukos G, Homicsko C, Trabectedin and Durvalumab Combination is Feasible – and Active in Relapsing Ovarian Cancer , Commentary, CCR 2022.
  • Sotirios Papadopoulos, Pantelis Koulouris, Georgia Tsoumakidou, Ana Dolcan, Stephane Cherix, Maurice Matter, Patrick Omoumi and Antonia Digklia Case report: TKIs induced lymphadenopathy in desmoid tumor patients, Frontiers in Endocrinology 2022 (accepted)
  • Teixeira Farinha, H.; Digklia, A.; Schizas, D.; Demartines, N.; Schäfer, M.; Mantziari, S. Immunotherapy for Esophageal Cancer: State-of-the Art in 2021. Cancers 2022, 14, 554. https://doi.org/10.3390/cancers14030554
  • Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S,Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V,Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic J. Oncologie [2021 Oncology update]. Rev Med Suisse.2022 Feb 2;18(767):182-186. French. doi: 10.53738/REVMED.2022.18.767.182. PMID:35107893.
  • Stamatiou A, Jankovic J, Szturz P, Fasquelle F, Duran R, Schaefer N, DiciollaA, Digklia A. Case Report: Vasculitis Triggered by SIRT in a Patient WithPreviously Untreated Cholangiocarcinoma. Front Oncol. 2021 Dec 16;11:755750.doi: 10.3389/fonc.2021.755750. PMID: 34976803; PMCID: PMC8716376.
  • Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, CristinaV, Stravodimou A, Veronica AL, Dolcan A, Sarivalasis A, Liapi A, Bouchaab H,Orcurto A, Dotta-Celio J, Peters S, Decosterd L, Widmer N, Wagner D, Csajka C,Schneider MP. Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication AdherenceProgram Along With Systematic Collection and Modeling of Pharmacokinetic andPharmacodynamic Data. JMIR Res Protoc. 2021 Jun 29;10(6):e30090. doi:10.2196/30090. PMID: 34185020; PMCID: PMC8278299.
  • Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M,Digklia A. Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases. Front Oncol. 2021 Jun 18;11:704295. doi: 10.3389/fonc.2021.704295. PMID: 34222029; PMCID: PMC8249751.
  • Djafarrian R, Zingg T, Digklia A, Becce F, Özsahin EM, La Rosa S, Demartines N, Matter M. Prise en charge des sarcomes des tissus mous abdominaux [Management of abdominal soft tissue sarcomas]. Rev Med Suisse. 2021 Jun 16;17(743):1172-1176. French. PMID: 34133095
  • Kokkali S, Stravodimou A, Duran-Moreno J, Koufopoulos N, Voutsadakis IA, Digklia A. Chemotherapy and targeted treatments of breast sarcoma by histologic subtype. Expert Rev Anticancer Ther. 2021 Feb 7. doi:10.1080/14737140.2021.1880327. Epub ahead of print. PMID: 33554686.
  • Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG,Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J. Oncologie [2020,33507661.
  • Girardet R, Boughdad S, Digklia A, Beigelman C, Meyer M, Schaefer N, Vermersch M, Hocquelet A, Tsoumakidou G, Denys A, Duran R. Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium. Cardiovasc Intervent Radiol. 2020 Nov;43(11):1712-1715. doi: 10.1007/s00270-020-02605-3. Epub 2020 Aug 5. PMID:32761249; PMCID: PMC7591430.
  • Denys A, Guiu B, Chevallier P, Digklia A, de Kerviler E, de Baere T. Interventional oncology at the time of COVID-19 pandemic: Problems and solutions. Diagn Interv Imaging. 2020 Jun;101(6):347-353. doi: 10.1016/j.diii.2020.04.005. Epub 2020 Apr 23. PMID: 32360351; PMCID: PMC7177103.
  • Keskin T, Bakaric A, Waszyk P, Boulay G, Torsello M, Cornaz-Buros S, Chevalier N, Geiser T, Martin P, Volorio A, Iyer S, Kulkarni A, Letovanec I, Cherix S, Cote GM, Choy E, Digklia A, Montemurro M, Chebib I, Nielsen PG,Carcaboso AM, Mora J, Renella R, Suvà ML, Fusco C, Provero P, Rivera MN, Riggi N, Stamenkovic I. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. Cell Rep. 2020 Apr 14;31(2):107539. doi: 10.1016/j.celrep.2020.107539. Erratum for: Cell Rep. 2020 Mar 31;30(13):4567-4583.e5. PMID: 32294441.
  • Keskin T, Bakaric A, Waszyk P, Boulay G, Torsello M, Cornaz-Buros S, Chevalier N, Geiser T, Martin P, Volorio A, Iyer S, Kulkarni A, Letovanec I, Cherix S, Cote GM, Choy E, Digklia A, Montemurro M, Chebib I, Nielsen PG,Carcaboso AM, Mora J, Renella R, Suvà ML, Fusco C, Provero P, Rivera MN, Riggi N, Stamenkovic I. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability. Cell Rep. 2020 Mar31;30(13):4567-4583.e5. doi: 10.1016/j.celrep.2019.12.053. Erratum in: Cell Rep.2020 Apr 14;31(2):107539. PMID: 32234488.
  • Duran-Moreno J, Kokkali S, Ramfidis V, Salomidou M, Digklia A, Koumarianou A,Tomos P, Koufopoulos N, Vamvakaris I, Psychogiou E, Syrigos K. Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases. Anticancer Res. 2020 Mar;40(3):1697-1703. doi: 10.21873/anticanres.14122.PMID: 32132077.
  • Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A. Oncologie [Advances in Oncology 2019]. Rev Med Suisse. 2020 Jan15;16(676-7):72-77. French. PMID: 31961089.
  • Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp. 2020 Jan 3;4(1):2. doi: 10.1186/s41747-019-0134-1. PMID: 31900689; PMCID: PMC6942076.
  • Policicchio A, Mercier J, Digklia A, Voutsadakis IA. Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer. J Gastrointest Cancer. 2019 Dec;50(4):894-900. doi: 10.1007/s12029-018-0173-5.PMID: 30353366.
  • Sivade A, Sempoux C, Voutsadakis I, Brunel C, Halkic N, Godat S, Duran R,Digklia A. Synchronous tumors of the pancreas and the gallbladder: a case report with targeted NGS evaluation. Ann Transl Med. 2019 Nov;7(22):696. doi: 10.21037/atm.2019.10.107. PMID: 31930097; PMCID: PMC6944562.
  • Ponti A, Denys A, Digklia A, Schaefer N, Hocquelet A, Knebel JF, Michielin O, Dromain C, Duran R. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med. 2020 Mar;61(3):350-356. doi: 10.2967/jnumed.119.230870. Epub 2019 Sep 3. PMID:31481579.
  • Bassani-Sternberg M*, Digklia A*, Huber F, Wagner D, Sempoux C, Stevenson BJ, Thierry AC, Michaux J, Pak H, Racle J, Boudousquie C, Balint K, Coukos G, Gfeller D, Martin Lluesma S, Harari A, Demartines N, Kandalaft LE. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients. Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. PMID: 31440238; PMCID: PMC6694698.
  • Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Front Pharmacol. 2019 May 9;10:450. doi: 10.3389/fphar.2019.00450. PMID: 31143114; PMCID: PMC6521126.
  • Nikolaou M, Nikolaou G, Digklia A, Pontas C, Tsoukalas N, Kyrgias G, Tolia M. Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419827090. doi: 10.1177/1534735419827090. PMID: 30791740; PMCID: PMC7242802.
  • Digklia A, Duran R, Homicsko K, Kandalaft LE, Hocquelet A, Orcurto A, Coukos G, Denys A. Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1221-1229. doi: 10.1007/s00270-018-2074-1. Epub 2018 Sep 12. PMID: 30209564.
  • Loriaud A, Denys A, Seror O, Vietti Violi N, Digklia A, Duran R, Trillaud H,Hocquelet A. Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. Int J Hyperthermia. 2018 Dec;34(8):1171-1178. doi: 10.1080/02656736.2018.1440017. Epub 2018 Apr 18. PMID: 29457510.
  • Vietti Violi N, Duran R, Guiu B, Cercueil JP, Aubé C, Digklia A, Pache I, Deltenre P, Knebel JF, Denys A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018 May;3(5):317-325. doi: 10.1016/S2468-1253(18)30029-3. Epub 2018 Mar 2. PMID: 29503247.
  • Parisod L, Duran R, Denys A, Digklia A. Carcinome hépatocellulaire avancé : nouveautés de la thérapie systémique et place du traitement local ? [Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy]. Rev Med Suisse. 2017 May 17;13(563):1032-1034. French. PMID: 28636293.
  • Skafida E, Kokkali S, Nikolaou M, Digklia A. Metastatic soft tissue sarcoma: current treatment landscape and future perspectives. Expert Rev Anticancer Ther.2017 Jun;17(6):537-543. doi: 10.1080/14737140.2017.1321989. Epub 2017 Apr 28. PMID: 28425820.
  • Cherix S, Vauclair F, Morattel B, Vautrin M, Matter M, Montemurro M, DigkliaA, Letovanec I, Omoumi P, Saucy F, Gonzalez M, Durham AD, Bosisio F, Zyska Cherix AC, Rudiger HA. Centre des sarcomes : un nouvel outil pour améliorer laprise en charge du patient et soutenir la recherche [Sarcoma centres : a necessary tool in the management of patients and for research.]. Rev Med Suisse. 2016 Dec 14;12(543):2172-2176. French. PMID: 28707833.
  • Digklia A, Michielin O. The cutting edge of metastatic melanoma therapy. Melanoma Manag. 2016 Sep;3(3):217-229. doi: 10.2217/mmt-2016-0026. Epub 2016 Aug 22. PMID: 30190891; PMCID: PMC6094682.
  • Allemann P, Mantziari S, Wagner D, Digklia A, Ozsahin E, De Bari B, Dorta G, Godat S, Montserrat F, Sempoux C, Brunel C, Demartines N, Schäfer M. Traitement curatif du cancer de l'oesophage: consensus multidisciplinaire multicentrique [Curative treatment for esophageal cancer: results of a multidisciplinary consensus]. Rev Med Suisse. 2016 Jun 15;12(523):1165-9. French. PMID: 27487620.
  • Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 2016 Feb 28;22(8):2403-14. doi: 10.3748/wjg.v22.i8.2403. PMID: 26937129; PMCID: PMC4768187.
  • Digklia A, Voutsadakis IA. Eribulin for heavily pre-treated metastatic breast cancer patients. World J Exp Med. 2015 Aug 20;5(3):194-9. doi:10.5493/wjem.v5.i3.194. PMID: 26309821; PMCID: PMC4543814.
  • Diciolla A, Cristina V, De Micheli R, Digklia A, Wagner AD. Nouveautés et perspectives dans la prise en charge des cancers colorectaux et gastriques avancés [News and perspectives in the treatment of advanced gastric and colorectal cancers]. Rev Med Suisse. 2015 May 20;11(475):1122, 1124-6. French. PMID: 26152087.
  • Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med. 2014 Nov 20;4(4):58-67. doi: 10.5493/wjem.v4.i4.58. PMID: 25414818; PMCID: PMC4237643.
  • Digklia A, Voutsadakis IA. Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer. Obstet Gynecol Sci. 2014 Nov;57(6):457-63.doi: 10.5468/ogs.2014.57.6.457. Epub 2014 Nov 20. PMID: 25469333; PMCID:PMC4245338.
  • Panos GD, Panos LD, Digklia A, Hafezi F, Gatzioufas Z. Unusual presentation of cerebral venous sinus thrombosis associated with contraceptive usage. J Ophthalmic Vis Res. 2014 Apr;9(2):281-4. PMID: 25279133; PMCID: PMC4181214.
  • Digklia A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. World J Gastrointest Oncol. 2013 May 15;5(5):88-96. doi:10.4251/wjgo.v5.i5.88. PMID: 23799158; PMCID: PMC3682173.
  • Digklia A, Tzika E, Voutsadakis IA. Cutaneous leukocytoclastic vasculitis associated with letrozole. J Oncol Pharm Pract. 2014 Apr;20(2):146-8. doi: 10.1177/1078155213480535. Epub 2013 May 14. PMID: 23676512.
  • Digklia A, Voutsadakis IA. Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole. Chemotherapy. 2012;58(6):435-8. doi: 10.1159/000345793. Epub 2013 Jan 12. PMID: 23327989.

Are you interested in submitting your research paper?

Thank you for choosing us. We recommend you to go through our guidelines before submitting the paper.

Submit Manuscript
Logo

Clinical Oncology Journal is the state-of-the-art platform to showcase medical journals across scientific community and a one-stop solution for publishing the manuscripts of varied medical specialities.

Main Links

Useful Links

Our Contacts

CLINICAL ONCOLOGY JOURNAL,
C/O Infact Publications LLC,
16192 Coastal Highway,
Lewes, Delaware 19958
USA

info@clinicaloncologyjournal.com
https://clinicaloncologyjournal.com